1. Home
  2. DRMA vs CPHI Comparison

DRMA vs CPHI Comparison

Compare DRMA & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DRMA
  • CPHI
  • Stock Information
  • Founded
  • DRMA 2014
  • CPHI N/A
  • Country
  • DRMA United States
  • CPHI China
  • Employees
  • DRMA N/A
  • CPHI N/A
  • Industry
  • DRMA Biotechnology: Pharmaceutical Preparations
  • CPHI Biotechnology: Pharmaceutical Preparations
  • Sector
  • DRMA Health Care
  • CPHI Health Care
  • Exchange
  • DRMA Nasdaq
  • CPHI Nasdaq
  • Market Cap
  • DRMA 4.5M
  • CPHI 5.4M
  • IPO Year
  • DRMA 2021
  • CPHI N/A
  • Fundamental
  • Price
  • DRMA $0.82
  • CPHI $1.91
  • Analyst Decision
  • DRMA Strong Buy
  • CPHI
  • Analyst Count
  • DRMA 1
  • CPHI 0
  • Target Price
  • DRMA $6.00
  • CPHI N/A
  • AVG Volume (30 Days)
  • DRMA 282.9K
  • CPHI 128.4K
  • Earning Date
  • DRMA 05-19-2025
  • CPHI 05-14-2025
  • Dividend Yield
  • DRMA N/A
  • CPHI N/A
  • EPS Growth
  • DRMA N/A
  • CPHI N/A
  • EPS
  • DRMA N/A
  • CPHI N/A
  • Revenue
  • DRMA N/A
  • CPHI $4,528,929.00
  • Revenue This Year
  • DRMA N/A
  • CPHI N/A
  • Revenue Next Year
  • DRMA N/A
  • CPHI N/A
  • P/E Ratio
  • DRMA N/A
  • CPHI N/A
  • Revenue Growth
  • DRMA N/A
  • CPHI N/A
  • 52 Week Low
  • DRMA $0.69
  • CPHI $1.20
  • 52 Week High
  • DRMA $6.17
  • CPHI $4.10
  • Technical
  • Relative Strength Index (RSI)
  • DRMA 43.16
  • CPHI 50.00
  • Support Level
  • DRMA $0.73
  • CPHI $1.73
  • Resistance Level
  • DRMA $0.99
  • CPHI $2.00
  • Average True Range (ATR)
  • DRMA 0.08
  • CPHI 0.22
  • MACD
  • DRMA 0.02
  • CPHI 0.04
  • Stochastic Oscillator
  • DRMA 34.93
  • CPHI 58.56

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc. is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.

About CPHI China Pharma Holdings Inc.

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.

Share on Social Networks: